Exposure-response of ciclosporin and methotrexate in children and young people with severe atopic dermatitis: a secondary analysis of the TREatment of severe Atopic dermatitis Trial (TREAT).

Wan M., Jones AP., Maskrey D., Arenas-Hernandez M., Rosala-Hallas A., Beattie PE., Baron S., Browne F., Brown SJ., Gach JE., Greenblatt D., Hearn R., Hilger E., Esdaile B., Cork MJ., Howard E., Lovgren M-L., August S., Ashoor F., Williamson PR., McPherson T., O'Kane D., Ravenscroft J., Shaw L., Sinha MD., Spowart C., Thomas BR., Sach TH., Irvine AD., Flohr C.

This is a secondary analysis of a multicentre randomized controlled trial of ciclosporin and methotrexate in children and young people (CYP) with severe atopic dermatitis (AD). Longitudinal trough ciclosporin and erythrocyte methotrexate polyglutamate (MTX-PG) concentrations were measured to evaluate their associations with treatment response and adverse events. Both ciclosporin (4 mg kg-1 daily) and methotrexate (0.4 mg kg-1 weekly) led to a significant reduction in disease severity scores over the 36-week treatment period. Higher trough ciclosporin concentrations were associated with lower disease severity scores and may serve as a useful tool for therapeutic drug monitoring of ciclosporin in CYP with AD. However, in contrast to a previously published study, steady-state erythrocyte-MTX-PG concentrations showed no significant association with treatment response. Drug concentrations were comparable between patients with and without drug-related adverse events.

DOI

10.1093/ced/llaf147

Type

Journal article

Publication Date

2025-07-24T00:00:00+00:00

Volume

50

Pages

1623 - 1627

Total pages

4

Keywords

Adolescent, Child, Child, Preschool, Female, Humans, Male, Young Adult, Cyclosporine, Dermatitis, Atopic, Dermatologic Agents, Drug Monitoring, Immunosuppressive Agents, Methotrexate, Polyglutamic Acid, Severity of Illness Index, Treatment Outcome

Permalink More information Close